Literature DB >> 32560770

Economic impact of health resource optimisation in the approach to patients with hepatitis C.

Juan Turnes1, Federico García2, Moisés Diago3, Raúl J Andrade4, Pilar Díaz5, Darío Rubio-Rodríguez6, Carlos Rubio-Terrés6.   

Abstract

TThe incorporation of direct-acting antiviral agents to the treatment of chronic hepatitis C infection has simplified diagnosis and follow-up, allowing optimisation of health resources (consultations and tests) dedicated to the management of the disease. The aim of this study was to estimate the economic impact of this simplification. Health resource optimisation was estimated through the Delphi method, based on a panel of 36 experts, consisting of Spanish clinicians, and on clinical practice guidelines. The unit costs (€ in 2017) of the health resources included were obtained from Spanish sources. Simplification of the process, as well as liaison between the medical specialist, nurses and the pharmacy service, would generate savings of €591.17 per patient. Likewise, the mean length of consultations would be shorter with regimens of only 1 tablet daily compared with regimens of more than 1 tablet daily. Supplement information: This article is part of a supplement entitled "The value of simplicity in hepatitis C treatment", which is sponsored by Gilead. © 2019 Elsevier España, S.L.U. All rights reserved.
Copyright © 2019 Elsevier España, S.L.U. Todos los derechos reservados.

Entities:  

Keywords:  Direct-acting antiviral; Fármacos antivirales de; Healthcare resources; Hepatitis C; Hepatitis C treatment; Recursos asistenciales; Tratamiento de la; acción directa; agents; hepatitis C

Year:  2019        PMID: 32560770     DOI: 10.1016/S0210-5705(20)30185-0

Source DB:  PubMed          Journal:  Gastroenterol Hepatol        ISSN: 0210-5705            Impact factor:   2.102


  1 in total

1.  Analysis of the Health and Budgetary Impact of Chondroitin Sulfate Prescription in the Treatment of Knee Osteoarthritis Compared to NSAIDs and COXIBs.

Authors:  Carlos Rubio-Terrés; Miguel Bernad Pineda; Marta Herrero; Carlos Nieto; Darío Rubio-Rodríguez
Journal:  Clinicoecon Outcomes Res       Date:  2020-09-14
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.